A longer administration period beyond 4 weeks may be necessary to achieve statistically significant results, as previous research in metabolic disease models suggests that treatment durations of 8 to 12 weeks are required to detect changes in markers such as body weight and insulin [93]. This evidence concerns the gene INS and metabolic disease.